Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01182233 | Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic Stem Cell Transplantation | terminated | Phase 1 | 4 | University of RochesterOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT01807286 | Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis | terminated | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | terminated | Phase 1 / Phase 2 | 4 | Baylor College of MedicineOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT01023880 | Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy | terminated | Phase 1 / Phase 2 | 62 | CephalonINDUSTRY | 1 | Apr 11, 2016 | clinicaltrials |
| NCT00615589 | Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen | terminated | Phase 2 | 22 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT01518153 | Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01624701 | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | terminated | Phase 1 / Phase 2 | 3 | Singapore General HospitalOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection | terminated | Phase 1 | 72 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2015 | clinicaltrials |
| NCT01889420 | Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 1 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 31, 2015 | clinicaltrials |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | terminated | Phase 1 | 2 | Celgene CorporationINDUSTRY | 1 | Jul 28, 2015 | clinicaltrials |
| NCT00431340 | A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma | terminated | Phase 2 | 4 | Valerio TherapeuticsINDUSTRY | 1 | Jul 8, 2015 | clinicaltrials |
| NCT00522392 | Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone | terminated | Phase 3 | 48 | National Cancer Institute (NCI)NIH | 2 | Jun 26, 2015 | clinicaltrials |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy | terminated | Phase 1 | 11 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | terminated | Phase 1 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00395967 | AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone | terminated | Phase 2 | 5 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | May 1, 2015 | clinicaltrials |
| NCT01062230 | Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 6 | University of ArkansasOTHER | 1 | Apr 6, 2015 | clinicaltrials |
| NCT00748631 | Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.(KYPHOK) | terminated | N/A | 60 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 24, 2015 | clinicaltrials |
| NCT02353468 | Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant | terminated | Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT02353572 | Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT00005834 | S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma | terminated | Phase 3 | 19 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00891033 | Panobinostat/Velcade in Multiple Myeloma | terminated | Phase 1 | 12 | University of ArkansasOTHER | 1 | Feb 23, 2015 | clinicaltrials |
| NCT01449539 | Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization | terminated | N/A | 8 | University of ArkansasOTHER | 1 | Feb 23, 2015 | clinicaltrials |
| NCT01302366 | A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma | terminated | Phase 2 | 20 | NYU Langone HealthOTHER | 1 | Feb 12, 2015 | clinicaltrials |
| NCT01537861 | Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma | terminated | Early Phase 1 | 7 | Washington University School of MedicineOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00719901 | Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2015 | clinicaltrials |
| NCT01078441 | Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2015 | clinicaltrials |
| NCT01653418 | Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation(V-BEAM) | terminated | Phase 2 | 10 | Washington University School of MedicineOTHER | 1 | Oct 15, 2014 | clinicaltrials |
| NCT00594308 | In-Vivo Activated T-Cell Depletion to Prevent GVHD | terminated | N/A | 10 | Indiana UniversityOTHER | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00675428 | Study of Natalizumab in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | BiogenINDUSTRY | 1 | Sep 19, 2014 | clinicaltrials |
| NCT00240162 | PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma | terminated | Phase 2 | 21 | Washington University School of MedicineOTHER | 1 | Sep 17, 2014 | clinicaltrials |
| NCT01301963 | Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide | terminated | Phase 3 | 9 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2014 | clinicaltrials |
| NCT02079519 | A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma | terminated | Phase 2 | 10 | Hoffmann-La RocheINDUSTRY | 1 | Jul 8, 2014 | clinicaltrials |
| NCT00872300 | PHA-739358 for the Treatment of Multiple Myeloma | terminated | Phase 2 | 7 | Nerviano Medical SciencesINDUSTRY | 2 | May 28, 2014 | clinicaltrials |
| NCT01309412 | A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 9 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | May 19, 2014 | clinicaltrials |
| NCT00293111 | Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM) | terminated | Phase 2 | 30 | CephalonINDUSTRY | 1 | May 12, 2014 | clinicaltrials |
| NCT00215943 | Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) | terminated | Phase 3 | 90 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 2 | Apr 17, 2014 | clinicaltrials |
| NCT00441168 | Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma | terminated | Phase 2 | 30 | Janssen-Cilag International NVINDUSTRY | 7 | Mar 21, 2014 | clinicaltrials |
| NCT00943293 | Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies | terminated | Phase 1 | 1 | University of ChicagoOTHER | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00396383 | Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation | terminated | Phase 2 | 9 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00499239 | A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 32 | Gilead SciencesINDUSTRY | 3 | Feb 4, 2014 | clinicaltrials |
| NCT00590603 | Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma(AAV) | terminated | Phase 1 | 25 | Duke UniversityOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT00412919 | Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 7 | Bayside HealthOTHER_GOV | 1 | Dec 16, 2013 | clinicaltrials |
| NCT00899353 | Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) | terminated | Phase 2 | 16 | Marshall UniversityOTHER | 1 | Dec 12, 2013 | clinicaltrials |
| NCT00361088 | A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 42 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT01500161 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | terminated | Phase 2 | 1 | Texas Oncology Cancer CenterINDUSTRY | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00718640 | An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function | terminated | Phase 2 | 10 | Janssen-Ortho Inc., CanadaINDUSTRY | 1 | Oct 29, 2013 | clinicaltrials |
| NCT00243035 | Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00965861 | SCRI Tissue Testing Registry | terminated | — | 20 | SCRI Development Innovations, LLCOTHER | 1 | Aug 28, 2013 | clinicaltrials |
| NCT00514722 | Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies | terminated | N/A | 4 | University of California, San FranciscoOTHER | 1 | Aug 14, 2013 | clinicaltrials |
| NCT00241371 | A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 8 | Washington University School of MedicineOTHER | 1 | Aug 13, 2013 | clinicaltrials |
Data updated 22 days agoSource updated May 17, 2016source: clinicaltrials